$276 Million is the total value of Decheng Capital Management III (Cayman), LLC's 26 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALPN | Buy | Alpine Immune Sciences, Inc. | $48,300,000 | +20.5% | 6,708,288 | +42.5% | 17.51% | +15.3% |
| ZNTL | Zentalis Pharmaceuticals Inc. | $39,520,000 | -22.9% | 1,824,583 | 0.0% | 14.33% | -26.3% | |
| Cue Health Inc. | $27,033,000 | -5.9% | 8,980,909 | 0.0% | 9.80% | -10.1% | ||
| ILMN | Sell | Illumnia, Inc. | $24,829,000 | -12.7% | 130,138 | -15.6% | 9.00% | -16.5% |
| RCUS | Arcus BioSciences, Inc. | $22,754,000 | +3.2% | 869,790 | 0.0% | 8.25% | -1.3% | |
| RXDX | Prometheus Biosciences, Inc. | $14,753,000 | +109.0% | 250,000 | 0.0% | 5.35% | +99.9% | |
| ALBO | Buy | Albireo Pharma, Inc. | $12,068,000 | +17.2% | 623,342 | +20.3% | 4.38% | +12.1% |
| TXG | Buy | 10x Genomics, Inc. | $10,240,000 | -25.6% | 359,554 | +18.3% | 3.71% | -28.8% |
| EQ | Equillium Inc. | $9,873,000 | +8.8% | 4,447,308 | 0.0% | 3.58% | +4.0% | |
| PACB | Pacific Biosciences of California, Inc. | $8,505,000 | +31.5% | 1,463,872 | 0.0% | 3.08% | +25.7% | |
| ACET | Adicet Bio, Inc. | $8,248,000 | -2.6% | 580,000 | 0.0% | 2.99% | -6.9% | |
| Aadi Bioscience, Inc. | $7,437,000 | +14.7% | 526,329 | 0.0% | 2.70% | +9.7% | ||
| MRSN | Mersana Therapeutics, Inc. | $6,113,000 | +46.3% | 904,268 | 0.0% | 2.22% | +39.9% | |
| New | Apexigen, Inc. | $5,115,000 | – | 1,894,551 | +100.0% | 1.85% | – | |
| BYSI | Buy | BeyondSpring Inc. | $4,909,000 | -31.2% | 4,958,143 | +0.0% | 1.78% | -34.2% |
| HZNP | Buy | Horizon Therapeutics PLC | $4,883,000 | +10.5% | 78,900 | +42.4% | 1.77% | +5.6% |
| TERN | Terns Pharmaceuticals, Inc. | $4,207,000 | +137.5% | 714,285 | 0.0% | 1.52% | +127.3% | |
| Aura Biosciences, Inc. | $3,805,000 | +27.9% | 210,000 | 0.0% | 1.38% | +22.3% | ||
| SGEN | New | Seagen Inc. | $3,149,000 | – | 23,014 | +100.0% | 1.14% | – |
| Sema4 Holings Corp. | $3,002,000 | -30.3% | 3,418,929 | 0.0% | 1.09% | -33.4% | ||
| ARGX | New | Argenx SE | $1,952,000 | – | 5,529 | +100.0% | 0.71% | – |
| AtriCure Inc. | $1,809,000 | -4.3% | 46,259 | 0.0% | 0.66% | -8.5% | ||
| SCYX | Scynexis Inc. | $1,333,000 | +29.0% | 555,555 | 0.0% | 0.48% | +23.2% | |
| Owlet, Inc. | $961,000 | -37.1% | 898,400 | 0.0% | 0.35% | -39.9% | ||
| NAUT | Nautilus Biotechnology, Inc. | $636,000 | -21.2% | 300,000 | 0.0% | 0.23% | -24.5% | |
| NBSE | NeuBase Therapeutics, Inc. | $395,000 | -62.4% | 1,000,000 | 0.0% | 0.14% | -64.1% | |
| OMIC | Exit | Singular Genomics Systems, Inc. | $0 | – | -20,000 | -100.0% | -0.03% | – |
| MASS | Exit | 908 Devices Inc. | $0 | – | -20,000 | -100.0% | -0.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Illumnia, Inc. | 7 | Q3 2023 | 16.5% |
| Cue Health Inc. | 7 | Q3 2023 | 17.8% |
| Arcus BioSciences, Inc. | 7 | Q3 2023 | 8.4% |
| 10x Genomics, Inc. | 7 | Q3 2023 | 8.1% |
| Pacific Biosciences of California, Inc. | 7 | Q3 2023 | 6.8% |
| Equillium Inc. | 7 | Q3 2023 | 4.3% |
| Aadi Bioscience, Inc. | 7 | Q3 2023 | 2.7% |
| Adicet Bio, Inc. | 7 | Q3 2023 | 3.6% |
| Aura Biosciences, Inc. | 7 | Q3 2023 | 6.1% |
| Terns Pharmaceuticals, Inc. | 7 | Q3 2023 | 3.4% |
View Decheng Capital Management III (Cayman), LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-01-22 |
| 13F-HR/A | 2023-12-12 |
| 13F-HR/A | 2023-11-29 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-07-28 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-08 |
| 4 | 2022-09-27 |
| 13F-HR | 2022-08-01 |
View Decheng Capital Management III (Cayman), LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.